Abstract
Nuclear erythroid factor 2 like 2 (Nrf2) has been described as a transcription factor that serves as a master regulator of the adaptive response to exogenous and endogenous oxidative and electrophilic stresses. Evidence of Nrf2 crosstalk with other molecular pathways is increasing; recent publications have proposed a role of Nrf2 in the development of obesity and in the highly regulated process of adipocyte differentiation through its interaction with other transcription factors and receptors implicated in metabolic regulation. In the present review, we discuss the available data on the possible role of Nrf2 in obesity and metabolic syndrome and the feasibility of using Nrf2 as a therapeutic target in the clinical setting.
Keywords: Diabetes, Keap1, Metabolism, Nrf2, obesity, Oxidative stress, endogenous, exogenous, Body Mass Index, sulfonylureas.
Current Diabetes Reviews
Title:New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome
Volume: 9 Issue: 2
Author(s): Dionysios V. Chartoumpekis and Thomas W. Kensler
Affiliation:
Keywords: Diabetes, Keap1, Metabolism, Nrf2, obesity, Oxidative stress, endogenous, exogenous, Body Mass Index, sulfonylureas.
Abstract: Nuclear erythroid factor 2 like 2 (Nrf2) has been described as a transcription factor that serves as a master regulator of the adaptive response to exogenous and endogenous oxidative and electrophilic stresses. Evidence of Nrf2 crosstalk with other molecular pathways is increasing; recent publications have proposed a role of Nrf2 in the development of obesity and in the highly regulated process of adipocyte differentiation through its interaction with other transcription factors and receptors implicated in metabolic regulation. In the present review, we discuss the available data on the possible role of Nrf2 in obesity and metabolic syndrome and the feasibility of using Nrf2 as a therapeutic target in the clinical setting.
Export Options
About this article
Cite this article as:
Chartoumpekis V. Dionysios and Kensler W. Thomas, New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome, Current Diabetes Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573399811309020005
DOI https://dx.doi.org/10.2174/1573399811309020005 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessment of a Synthetic Steroid and Flutamide on Dopamine, GSH and H<sub>2</sub>O<sub>2</sub> Levels in Rat Brain in Presence of Fructose
Endocrine, Metabolic & Immune Disorders - Drug Targets Photodynamic Therapy using Carbohydrate Conjugated Porphyrins
Drug Design Reviews - Online (Discontinued) Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Molecular Mechanisms of Anti-cancer Action of Garlic Compounds in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Anticancer Perspectives on the Fungal-Derived Polyphenolic Hispolon
Anti-Cancer Agents in Medicinal Chemistry Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Drug Delivery Letters Preface
Current Pharmaceutical Design Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Targeting Dopaminergic System for Treating Nicotine Dependence
Central Nervous System Agents in Medicinal Chemistry Recent Patents on Biomarkers in Oral Cancers
Recent Patents on Biomarkers Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics Anticancer Activity of New Haloalkyl Camptothecin Esters against Human Cancer Cell Lines and Human Tumor Xenografts Grown in Nude Mice
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Current Signal Transduction Therapy The Use of Mathematical Modelling for Improving the Tissue Engineering of Organs and Stem Cell Therapy
Current Stem Cell Research & Therapy